Having led multiple therapeutics and healthcare organizations as CEO, Steven brings an exceptional track record as an executive to the Board of Directors here at DermBiont, the world’s leading skin microbiome therapeutics company.
BOSTON (PRWEB) May 14, 2020
DermBiont, a clinical stage microbiome biotechnology company developing topical live biotherapeutics, is pleased to announce that Mr. Steven Basta has been appointed to the company's board of directors, effective immediately.
“Having led multiple therapeutics and healthcare organizations as CEO, Steven brings an exceptional track record as an executive to the Board of Directors here at DermBiont, the world’s leading skin microbiome therapeutics company. Our entire leadership team is excited to benefit from his experience as we continue to advance our discovery programs and products in development,” said Karl Beutner, CEO of DermBiont.
"DermBiont has built an incredible platform and culture that enables the company to discover and advance microbial therapeutics through the clinic much faster and more efficiently than traditional therapeutics," said Steven Basta. "I look forward to working with Karl and the leadership team. The entire DermBiont organization is committed to developing novel therapeutics that treat skin diseases at their root cause, a dysbiosis of the cutaneous microbiome."
Mr. Basta most recently served as the President and CEO of Menlo Therapeutics, a dermatology therapeutics development company. Mr. Basta previously served as CEO at AlterG Inc, BioForm medical (acquired by Merz), Merz Aesthetics, and Gliatech. He currently sits on the board of Menlo Therapeutics, and serves as the Chairman of the Board of Viveve Medical.
DermBiont’s other current board members are: Karl Beutner, CEO, DermBiont (formerly CMO of Anacor, sold to Pfizer for $5.2B in 2016); Wilder Ramsey, Partner, Toba Capital; Nichola Eliovits, Managing Partner, Olive Tree Capital.
DermBiont is the world’s leading dermatology company leveraging skin microbiome therapeutics (live biotherapeutics) to treat the root cause of skin diseases. In addition to the company’s lead product in development to treat Onychomycosis and Atopic Dermatitis, DBI-001, the company is advancing four other clinical assets across a wide range of skin diseases caused by a dysbiosis of the microbiome. The company’s discovery capabilities are powered by a proprietary computational biology platform enabling the rapid discovery of hits against pathogens from a curated library of thousands of microbes isolated from human skin and one of the world’s largest data sets of Nextgen sequencing of the human microbiome across healthy and diseased skin.
Send all inquiries to: firstname.lastname@example.org